Clinical Trials
6
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Phase 1 Study of TG02 Citrate in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
- Conditions
- Small Lymphocytic LymphomaChronic Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2012-10-03
- Last Posted Date
- 2019-07-25
- Lead Sponsor
- Tragara Pharmaceuticals, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT01699152
- Locations
- 🇺🇸
GRU, Augusta, Georgia, United States
🇺🇸DFCI, Boston, Massachusetts, United States
🇺🇸OSU, Columbus, Ohio, United States
Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
- Conditions
- Blast CrisisAMLMultiple MyelomaALLMDS
- Interventions
- First Posted Date
- 2010-09-17
- Last Posted Date
- 2016-05-06
- Lead Sponsor
- Tragara Pharmaceuticals, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT01204164
- Locations
- 🇺🇸
RMCC, Denver, Colorado, United States
🇺🇸Emory, Atlanta, Georgia, United States
🇺🇸Rush, Chicago, Illinois, United States
APRiCOT-P: Study of Apricoxib With Gemcitabine and Erlotinib to Treat Advanced Pancreatic Cancer
- Conditions
- Pancreatic CancerMetastatic Pancreatic Cancer
- Interventions
- First Posted Date
- 2008-07-03
- Last Posted Date
- 2012-11-07
- Lead Sponsor
- Tragara Pharmaceuticals, Inc.
- Target Recruit Count
- 109
- Registration Number
- NCT00709826
- Locations
- 🇺🇸
Arizona Clinical Research Center, Tucson, Arizona, United States
🇺🇸Comprehensive Blood and Cancer Center, Bakersfield, California, United States
🇺🇸Southbay Oncology Hematology Partners, Campbell, California, United States
APRiCOT-B: Study to Evaluate Apricoxib in Combination With Lapatinib and Capecitabine in the Treatment of HER2/Neu+ Breast Cancer (TP2001-202)
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2008-04-14
- Last Posted Date
- 2012-03-15
- Lead Sponsor
- Tragara Pharmaceuticals, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT00657137
- Locations
- 🇺🇸
Arizona Clinical Research Center, Tucson, Arizona, United States
🇺🇸Comprehensive Blood and Cancer Center, Bakersfield, California, United States
🇺🇸Alta Bates Summit Comprehensive Cancer Center, Berkeley, California, United States
APRiCOT-L: Study to Evaluate Efficacy and Safety of Apricoxib With Erlotinib in Patients With Non-small Cell Lung Cancer
- Conditions
- Recurrent Non Small Cell Lung Cancer
- Interventions
- Drug: apricoxib/erlotinibDrug: erlotinib/placebo
- First Posted Date
- 2008-04-03
- Last Posted Date
- 2012-04-09
- Lead Sponsor
- Tragara Pharmaceuticals, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT00652340
- Prev
- 1
- 2
- Next